Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - posaconazole, quantity: 100 mg - tablet, enteric coated - excipient ingredients: hypromellose acetate succinate; magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica; croscarmellose sodium; hyprolose; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - posaconazole is indicated for use in the treatment of the following invasive fungal infections in patients 13 years of age or older: invasive aspergillosis in patients intolerant of, or with disease that is refractory to, alternative therapy. fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma in patients intolerant of, or with disease that is refractory to, alternative therapy.,posaconazole is also indicated for the: prophylaxis of invasive fungal infections among patients 13 years of age and older, who are at high risk of developing these infections, such as patients with prolonged neutropenia or haematopoietic stem cell transplant (hsct) recipients.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - posaconazole, quantity: 100 mg - tablet, enteric coated - excipient ingredients: magnesium stearate; croscarmellose sodium; hyprolose; microcrystalline cellulose; hypromellose acetate succinate; colloidal anhydrous silica; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - posaconazole is indicated for use in the treatment of the following invasive fungal infections in patients 13 years of age or older: invasive aspergillosis in patients intolerant of, or with disease that is refractory to, alternative therapy. fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma in patients intolerant of, or with disease that is refractory to, alternative therapy.,posaconazole is also indicated for the: prophylaxis of invasive fungal infections among patients 13 years of age and older, who are at high risk of developing these infections, such as patients with prolonged neutropenia or haematopoietic stem cell transplant (hsct) recipients.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - posaconazole, quantity: 100 mg - tablet, enteric coated - excipient ingredients: magnesium stearate; croscarmellose sodium; hypromellose acetate succinate; hyprolose; microcrystalline cellulose; colloidal anhydrous silica; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - posaconazole is indicated for use in the treatment of the following invasive fungal infections in patients 13 years of age or older: invasive aspergillosis in patients intolerant of, or with disease that is refractory to, alternative therapy. fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma in patients intolerant of, or with disease that is refractory to, alternative therapy.,posaconazole is also indicated for the: prophylaxis of invasive fungal infections among patients 13 years of age and older, who are at high risk of developing these infections, such as patients with prolonged neutropenia or haematopoietic stem cell transplant (hsct) recipients.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - posaconazole, quantity: 100 mg - tablet, enteric coated - excipient ingredients: hyprolose; magnesium stearate; croscarmellose sodium; colloidal anhydrous silica; microcrystalline cellulose; hypromellose acetate succinate; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - posaconazole is indicated for use in the treatment of the following invasive fungal infections in patients 13 years of age or older: invasive aspergillosis in patients intolerant of, or with disease that is refractory to, alternative therapy. fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma in patients intolerant of, or with disease that is refractory to, alternative therapy.,posaconazole is also indicated for the: prophylaxis of invasive fungal infections among patients 13 years of age and older, who are at high risk of developing these infections, such as patients with prolonged neutropenia or haematopoietic stem cell transplant (hsct) recipients.

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

pharmatrade switzerland - 50 sachets - granules - 1g/sachet - gastrointestinal system-chronic bowel disorders

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - posaconazole, quantity: 40 mg/ml - oral liquid, suspension - excipient ingredients: sodium benzoate; sodium citrate dihydrate; citric acid monohydrate; titanium dioxide; glycerol; xanthan gum; liquid glucose; peg-40 hydrogenated castor oil; purified water; peg-40 stearate; benzoic acid; glyceryl monostearate; methylcellulose; polysorbate 65; simethicone; sorbic acid; sulfuric acid; flavour - posaconazole is indicated for use in the treatment of the following invasive fungal infections in patients 13 years of age or older: ? invasive aspergillosis in patients intolerant of, or with disease that is refractory to, alternative therapy. ? fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma in patients intolerant of, or with disease that is refractory to, alternative therapy.,posaconazole is also indicated for the: ? treatment of oropharyngeal candidiasis in immunocompromised adults, including patients with disease that is refractory to itraconazole and fluconazole. ? prophylaxis of invasive fungal infections among patients 13 years of age and older, who are at high risk of developing these infections, such as patients with prolonged neutropenia or haematopoietic stem cell transplant (hsct) recipients.

United States - English - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - bisacodyl (unii: 10x0709y6i) (bisacodyl - unii:10x0709y6i) - bisacodyl 5 mg -  stimulant laxative  -relieves occasional constipation and irregularity  -this product generally produces bowel movement in 6 to 12 hours

United States - English - NLM (National Library of Medicine)

cardinal health - bisacodyl (unii: 10x0709y6i) (deacetylbisacodyl - unii:r09078e41y) - bisacodyl 10 mg - stimulant laxative

United States - English - NLM (National Library of Medicine)

cardinal health, inc. - bisacodyl (unii: 10x0709y6i) (bisacodyl - unii:10x0709y6i) - bisacodyl 10 mg - laxative for the relief of occasional constipation. bowel movement is generally produced in 15 minutes to 1 hour.

United States - English - NLM (National Library of Medicine)

par pharmaceutical inc. - posaconazole (unii: 6tk1g07bhz) (posaconazole - unii:6tk1g07bhz) - posaconazole delayed-release tablets are indicated for the treatment of invasive aspergillosis in adults and pediatric patients 13 years of age and older. posaconazole is indicated for the prophylaxis of invasive aspergillus and candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (hsct) recipients with graft-versus-host disease (gvhd) or those with hematologic malignancies with prolonged neutropenia from chemotherapy [see clinical studies (14.1)] as follows: - posaconazole delayed-release tablets : adults and pediatric patients 2 years of age and older who weigh greater than 40 kg - posaconazole oral suspension: adults and pediatric patients 13 years of age and older posaconazole oral suspension is indicated for the treatment of oropharyngeal candidiasis, including oropharyngeal candidiasis refractory to itraconazole and/or fluconazole in adults and pediatric patients 13 years of age and o